Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin (NASDAQ: AMRN) welcomed the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline update endorsing a broader approach to residual cardiovascular risk and recognizing icosapent ethyl (IPE) as an evidence-based adjunct for statin-treated patients with elevated triglycerides. The guideline highlights IPE's role in reducing ASCVD events beyond LDL-C lowering.
Amarin (NASDAQ: AMRN) announced additional REDUCE-IT subgroup analyses and mechanistic EPA data will be presented at the American College of Cardiology Annual Scientific Session & Expo, March 28-30, 2026 in New Orleans.
Highlighted presentations include a REDUCE-IT secondary analysis on patients at extreme cardiovascular risk (oral, March 29, 12:30pm CST) and an EPA inhibition of Lp(a) oxidation poster (March 28, 11:00am CST).
Amarin (NASDAQ: AMRN) highlighted a post hoc REDUCE-IT analysis published March 2026 in the European Journal of Preventive Cardiology showing icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost to hospitalization and death among 8,179 statin-treated participants followed for a median of five years.
The paper underscores patient-centered benefits of IPE (VASCEPA/VAZKEPA) and notes prior REDUCE-IT results influenced guideline inclusion.
Amarin (NASDAQ: AMRN) reported Q4 and full‑year 2025 results showing operational improvements and a tighter cost base. Total net revenue was $49.2M in Q4 (down 21% YoY); operating loss narrowed to $6.3M; cash and investments were $302.6M with no debt.
The company realized $31M of targeted $70M cost savings and recorded $36.2M of restructuring charges in 2025, with remaining charges expected in early 2026. The company finalized a long‑term European license and supply agreement for VAZKEPA and retained U.S. VASCEPA market leadership.
Amarin (NASDAQ: AMRN) used American Heart Month (Feb 23, 2026) to urge urgent action on underutilized, guideline‑supported cardiovascular therapies.
The company highlighted that 48.9% of U.S. adults live with CVD and cited evidence that cumulative CV event incidence can reach ~40% over 10 years, calling to “Review, Reassess, Refocus” care to close treatment gaps.
Amarin (NASDAQ: AMRN) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A pre-market press release will be issued, followed by a conference call with senior management at 8:00 a.m. ET.
Investors can join via telephone (US: 888-506-0062; international: 973-528-0011, access code 675507) or via webcast on the company Investor Relations website. A replay will be available online and by phone through August 25, 2026.
Amarin (NASDAQ: AMRN) commented on recent therapeutic advances for patients with elevated triglycerides and said its VASCEPA/VAZKEPA (icosapent ethyl) franchise is well positioned to benefit from broader category commercialization. The company noted VASCEPA has been prescribed >25 million times, is FDA approved for severe hypertriglyceridemia (TG ≥500 mg/dL) and for cardiovascular risk reduction as an adjunct to statin therapy, and cited REDUCE-IT results showing a 25% relative reduction in cardiovascular events in 8,179 patients. Amarin also highlighted a 2025 exclusive license with Recordati for commercialization across 59 countries, with VAZKEPA available in >20 countries.
Amarin (NASDAQ:AMRN) reported preliminary unaudited 2025 results and operational milestones, highlighting a year-end cash balance of $303 million, positive cash flow in Q4 2025 achieved ahead of prior expectations, and a debt-free balance sheet. The company realized ~50% of an estimated $70 million OPEX savings from its 2025 restructuring and expects the full savings by June 30, 2026. FY 2025 net revenue is expected to be $212–$217 million, with Q4 revenue of $48–$53 million. Amarin completed a long-term exclusive license and supply agreement with Recordati for VAZKEPA in 59 countries and secured regulatory approvals in South Korea and Singapore.
Amarin (NASDAQ: AMRN) presented a new REDUCE-IT post hoc aspirin analysis at AHA Scientific Sessions 2025 showing that icosapent ethyl significantly reduced cardiovascular events in high-risk, statin-treated patients with elevated triglycerides.
Among 8,179 participants (6,179 on aspirin), icosapent ethyl cut the primary endpoint by 28% in aspirin users (P<0.0001), with an absolute risk reduction 5.9% and NNT 17. Total primary events were reduced by 36% (RR 0.64; 95% CI 0.56–0.74). In the secondary prevention aspirin subgroup (n=4,867) total events fell 39% (RR 0.61; 95% CI 0.53–0.70).
The analysis found consistent benefit with or without aspirin and reported a safety profile in aspirin users consistent with the overall trial population.
Amarin (NASDAQ: AMRN) will present new analyses and mechanistic studies at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025.
Highlighted items include REDUCE-IT analyses of icosapent ethyl (VASCEPA/VAZKEPA) assessing cardiovascular outcomes with or without baseline aspirin use, plus mechanistic data on EPA effects on lipoprotein(a) oxidation, anti-inflammatory actions, and endothelial protection. Specific presentations are scheduled Nov 9–10, 2025, across Abstract Board, Population Science, and Basic Science zones.